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Abstract
Because the kidney allograft has the potential to function as an in-vivo flowcytometer and
facilitate the access of immune cells and kidney parenchymal cells in to the urinary space, we
hypothesized that mRNA profiling of urinary cells offers a noninvasive means of assessing the
kidney allograft status. We overcame the inherent challenges of urinary cell mRNA profiling by
developing pre-amplification protocols to compensate for low RNA yield from urinary cells and
by developing robust protocols for absolute quantification mRNAs using RT-PCR assays. Armed
with these tools, we undertook first single-center studies urinary cell mRNA profiling and then
embarked on the multicenter Clinical Trials in Organ Transplantation-04 study of kidney
transplant recipients. We report here our discovery and validation of diagnostic and prognostic
biomarkers of acute cellular rejection and of interstitial fibrosis and tubular atrophy (IF/TA). Our
urinary cell mRNA profiling studies, in addition to demonstrating the feasibility of accurate
diagnosis of acute cellular rejection and IF/TA in the kidney allograft, advance mechanistic and
potentially targetable biomarkers. Interventional trials, guided by urinary cell mRNA profiles, may
lead to personalized immunosuppression in recipients of kidney allografts.
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The number of individuals being treated for end stage kidney disease (ESRD) continues to
grow worldwide [1–3]. For those afflicted with ESRD, kidney transplantation results in
superior survival compared to maintenance dialysis [4, 5]. The adjusted first-year all-cause
mortality rate for the year 2010 was 268.8 per 1000 patient years at risk for patients
managed with hemodialysis, 121.4 for patients treated with peritoneal dialysis and only 54.4
for recipients of kidney allografts [1]. The salutary effect of kidney transplantation however
is realized by very few since because of the shortage of organs for transplantation. In the US
alone, each year, approximately 100,000 patients compete for the 11,000 deceased donor
kidneys available for transplantation [6].
There are multiple causes for the organ shortage crisis and the growth of the transplant wait
list [7]. It is well documented that acute rejection (AR) is a major contributor to allograft
failure and a significant contributor to the escalating wait list is the return of patients with a
failed graft to the list [8–12]. Reducing such graft failures would help mitigate the existing
crisis in organ availability.
We have focused our research efforts on reducing the impact of allograft failure. We
reasoned that better diagnosis of acute cellular rejection (ACR), the most common type of
AR, and of interstitial fibrosis and tubular atrophy (IF/TA) is an essential first step. We
review here our studies towards the development and validation of noninvasively
ascertainable diagnostic and prognostic biomarkers of kidney allograft status. We provide
first an overview of AR and chronic rejection, and follow this précis with our findings from
interrogating AR and chronic rejection with the use of urinary cell mRNA profiling.
Biology of Immune Rejection
Kidney allograft rejection is defined as functional and structural deterioration due to an
active immune response expressed by the recipient and directed at the transplanted organ
[13]. Alloreactivity is primarily but not exclusively directed at the proteins encoded by
genes located within the donor’s major histocompatibility complex region and involves a
highly coordinated action of multiple cell types and mediators with donor antigen-reactive
lymphocytes being the principal drivers of the immune repertory [14–16].
Two distinct but not mutually exclusive pathways, T-lymphocyte- based pathway and B-
lymphocyte-based pathway contributes to immune rejection of the transplanted organ. T
cell-mediated rejection is the commonest type of AR [15, 17–19]. In early 1970s, donor-
specific and cytolytically active T lymphocytes were identified within the rejecting
experimental or human allografts [20, 21]. These cytolytically active cells kill their target by
inducing apoptosis/necrosis via the Fas-Fas ligand pathway and the granule exocytosis
pathway in which perforin and granzyme B collaborate [22, 23]. Experiments in a number of
laboratories including ours have shown intrarenal expression of mRNA encoding proteins
involved in both major lytic pathways, and the differential expression of these molecular
executors of cytotoxicity during AR or chronic rejection of the human kidney allograft [24–
27].
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Robust data exist that antibodies contribute to the three major types of immune rejection;
hyperacute, acute or chronic [28–33]. The clinical introduction of highly sensitive assays to
detect circulating antibodies have improved our appreciation of the role of antibodies in the
pathogenesis of AR–a mechanism recognized as early as the 70s with the use of high-
sensitive antibody-dependent cell-mediated cytotoxicity assays in which recipient’s sera are
tested against 51 chromium labeled donor cells [34]. It is important to recognize however
that dichotomization of rejection in to either cellular or antibody based might be simplistic
and in reality both arms of immunity contribute to the rejection, albeit with one or the other
arm appearing dominant based on the tools used to interrogate the biology of rejection.
Indeed, we recently found that a third of the patients diagnosed as acute antibody mediated
rejection by the current Banff criteria also fulfilled the criteria for ACR, and that the
presence of concomitant ACR was an independent risk factor for kidney allograft failure
following biopsy confirmed diagnosis of complement component 4d (C4d) positive acute
antibody mediated rejection [35].
Although AR has garnered much attention, chronic rejection/chronic allograft nephropathy
(CAN) is the commonest feature of chronically failing allografts [36, 37]. Interstitial fibrosis
and tubular atrophy (IF/TA) are histologic features of chronic rejection and likely to be the
final common pathway for allograft failure [38–41]. It is highly likely that alloantigen driven
mechanisms as well as non-immune mechanisms contribute to the pathogenesis of IF/TA
[39, 42–49]. Among the several non-immune mechanisms implicated in chronic allograft
injury, the calcineurin inhibitors are prime suspects since cyclosporine as well as tacrolimus
induces TGF-β1 hyperexpression in a number of cell types including T-cells and renal
tubular cells [50–56]. As TGF-β1 is a potent fibrogenic cytokine and is involved in repair
following tissue injury, a TGF-β1-centered hypothesis for integrating immune and non-
immune events in the pathogenesis of chronic rejection/CAN (manifested by IF/TA) appears
biologically plausible (Figure 1) [57]. Experimental support for this formulation includes: (i)
increased intragraft expression of TGF-β1 mRNA and protein in grafts manifesting IF/TA
[57–59]; (ii) increased expression of microRNA-21 capable of targeting Smad-7, a negative
regulator of TGF-β1-signaling, in grafts manifesting IF/TA [60]; (iii) increased expression
of several proteins, induced by TGF-β1 and involved in fibrosis (e.g., vimentin) in kidney
grafts showing IF/TA [61, 62]; and (iv) the ability of calcineurin inhibitors to induce TGF-
β1 [50–56].
Our TGF-β1 centric hypothesis has received support from a number of interventional studies
including the recent findings in a preclinical model. In the male Fischer rat to male Lewis rat
kidney transplants, neutralizing activities of TGF-β using an anti-TGF-β antibody
successfully reduced the severity of chronic rejection of kidney allografts. Compared with a
control antibody-treated group, administration of anti-TGF-β monoclonal antibody was
associated with a significant reduction of proteinuria, serum creatinine, and prevented
decline of creatinine clearance. Moreover there was reduction of the severity of cellular
infiltration, tubular injury, and graft tissue fibrosis as well as the expression of fibrosis-
associated genes in renal allografts [63].
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Interrogation of Immune Rejection by Urinary Cell mRNA profiling
Acute rejection is diagnosed using the invasive needle core biopsy procedure. While the
procedure has become safer over the years, challenges and complications still exist including
sampling error, inter-observer variability, patient being on anticoagulant therapy, bleeding,
arteriovenous fistula, graft loss, and even death [64–66]. The financial costs of the procedure
are substantial as well and reported to average about $3,000 [67]. With an estimated
incidence of 0.4 biopsies/patient during the first year of transplantation, about 7,000 biopsies
at a cost of $21 million are estimated to have been done during the first year of
transplantation in the 17,671 patients who received their kidney grafts in 2011 [1, 68].
Development of urinary cell mRNA profiling as a noninvasive predictive
and diagnostic tool
Because ACR is distinguished by interstitial inflammation and tubulitis and given that graft
infiltrating cells gain entry into the kidney tubular space, we reasoned that the allograft may
function as an “in-vivo flow cytometer” and sort cells involved in rejection into the urine
(Figure 2) [69]. We therefore hypothesized that mRNA profiling of urinary cells could
provide a noninvasive means of diagnosing ACR. We developed quantitative polymerase
chain reaction (PCR) assays and mRNA profiling protocols and demonstrated in a series of
single center studies that urinary cell levels of mRNA encoding proteins implicated in
allograft rejection are predictive and/or diagnostic of ACR in human renal allografts [70–
75]. Our original observations and those of others [76] served as the stimuli for the Clinical
Trials in Organ Transplantation-04 (CTOT-04) multicenter study.
Weill Cornell Studies of Urinary Cell mRNA Profiling
We developed highly reproducible methods for urinary cell mRNA profiling [77, 78] and
quantification of mRNA abundance [79] and examined whether levels of mRNA encoding
cytotoxic attack molecules – perforin and granzyme B – are informative of human kidney
allograft status. With the use of competitive quantitative PCR assays and gene specific novel
DNA competitors designed and developed in our laboratory we found that urinary cell levels
of mRNA for perforin predicted ACR with a sensitivity of 83% and a specificity of 83%
while granzyme B mRNA levels predicted ACR with a sensitivity of 79% and a specificity
of 77% [70].
In our subsequent studies, we modified the real time quantitative PCR assay to quantify
absolute levels of mRNA [80]. We developed a “universal” standard curve (i.e., a single
standard curve for multiple mRNAs of interest) using a synthetic amplicon for absolute
quantification of transcripts in the urinary cells. With the use of real time quantitative PCR
assays, we found that not only levels of perforin and granzyme B are higher in urinary cells
from patients with AR compared to those without AR but also the levels of serine proteinase
inhibitor-9 (PI-9), an endogenous antagonist of granzyme B [72].
Intraepithelial homing of T cells is contingent upon the cell surface expression of CD103
protein [81, 82]. Since acute cellular rejection is exemplified by tubulitis with intraepithelial
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homing of alloreactive T cells [83], we reasoned that urinary cell levels of CD103 would be
diagnostic of ACR in the kidney allograft. This hypothesis was validated by the finding that
urinary cell levels of CD103 mRNA are higher in patients with ACR compared to those
without ACR [71].
Chemokines and their receptors play a primary role in the trafficking of cells to
inflammatory sites [84]. We hypothesized that urinary cell level of IP-10 and its receptor
CXCR3 would help capture intragraft inflammation. Our research hypothesis was also based
on elegant pre-clinical experimental studies implicating IP-10 and CXCR3 in inflammatory
diseases including allograft rejection [85, 86]. We found that AR is indeed predicted with a
sensitivity of 100% and a specificity of 78% using urinary cell levels of IP-10 mRNA, and
with a sensitivity of 63% and a specificity of 83% using urinary cell levels of CXCR3
mRNA [73].
In view of the dominant role of regulatory T cells (Treg) cells in the maintenance of self-
tolerance [87], and in view of the suppressive role of Treg in experimental models of
transplantation tolerance [88, 89], we reasoned that measurement of mRNA for FoxP3, a
specification factor of Treg, in urinary cells might provide insight into the outcome of an
episode of AR. Due to low abundance of RNA present in urinary cells, we further modified
the standard quantitative real time (RT)-PCR assay to a two-step PCR assay involving an
initial pre-amplification step that enables measurement of multiple mRNA species from very
small quantities of total RNA. With the use of pre-amplification enhanced PCR assays, we
identified that FoxP3 mRNA levels are not only increased in patients with AR but also
predicted reversal of AR with 90% sensitivity and 73% specificity as well as graft failure
within 6-months after the incident episode of AR [74].
Co-stimulatory receptors and negative regulatory receptors on immune cells play a critical
role in allograft rejection and tolerance. The OX40/OX40L proteins have also been
implicated in regulating the emergence of Tregs and modulating their suppressive activity. A
novel T-cell inhibitory pathway involves PD-1 and its ligands, PD-L1 and PD-L2 [90, 91].
In studies designed to characterize the expression patterns of co-stimulatory/inhibitory
molecules in urinary cells during an episode of ACR, we found that urinary cell mRNA
levels of OX40, OX40L, PD-1 but not the levels of PD ligand 1 or PD ligand 2 are
significantly higher in the urinary cells from the AR group than the stable group. Within the
AR group, levels of mRNA for OX40, OX40L and Foxp3 predicted AR reversal, while
OX40 mRNA levels predicted graft failure after AR [75].
Clinical Trials in Organ Transplantation-04 (CTOT-04) study
CTOT-04 is a National Institutes of health (NIH) sponsored prospective observational
multicenter study designed to investigate whether urinary cell levels of mRNA encoding for
the CD3ε, perforin, granzyme B, PI9, CD103, IP-10 and CXCR3, ascertained at the time of
biopsy, are diagnostic of AR and to determine whether mRNA profiles of sequential urine
specimens obtained at clinically stable time points predict the development of AR. We
measured two additional transcripts (TGF-β1 mRNA and 18S rRNA) for quality control. In
CTOT-04, 497 kidney transplant recipients were enrolled at 5 clinical sites and 485 of the
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497 provided 4300 urine specimens for urinary cell mRNA profiling. Among the 485
patients, 220 had at least one renal allograft biopsy for clinical (for-cause) or surveillance
reason. We designed CTOT-04 as an observational study with each of the 5 participating
sites being able to use site-specific immunosuppression and infection protocols with the
rationale that urine mRNA profiling results should be generalizable to the kidney transplant
population and not be restricted by the immunosuppressive regimen used in any one clinic.
We used WCMC protocol to obtain urine samples (~50 ml) sequentially with a pre-specified
schedule for collection (post-transplant days 3, 7, 15 and 30 and months 2, 3, 4, 5, 6, 9 and
12, and at the time of any kidney allograft biopsy- before treatment and at 2 weeks after
biopsy). Urine cell pellets were prepared at the clinical sites, stored at −80°C and shipped in
batches to our Gene Expression Monitoring Core at Weill Cornell.
RNA yield from urinary sediments
We isolated total RNA from the urinary cell pellets using a commercial kit (PureLink™
Micro-to-Midi total RNA purification system, Invitrogen) and measured the RNA quantity
(absorbance at 260 nm) by NanoDrop® ND-1000 UV spectrophotometer. We examined
whether the amount of RNA isolated from the urinary sediment varied by allograft diagnosis
and/or clinical status of the graft recipient. In the CTOT-04 study, urine collection, urine
sediment preparation and RNA isolation were all performed using the protocol developed in
our laboratory and all RNA quantification was carried out using NanoDrop® ND-1000 UV
spectrophotometer. Our data analysis showed that the total amount of RNA isolated from the
urine sediment does not vary by allograft diagnosis and/or clinical status. The amount of
total RNA isolated from the urine sediment (median and 25th percentile and 75th percentile)
was 582 ng (381 ng and 973 ng) in the 43 biopsy-matched urine specimens collected from
34 kidney graft recipients with biopsies showing ACR (ACR Biopsy group), 476 ng (309 ng
and 760 ng) in the 163 biopsy-matched urine specimens collected from 126 kidney graft
recipients with biopsies showing no rejection (No Rejection Biopsy group), and 534 ng (307
ng and 918 ng)in the 1540 urine specimens from the 202 kidney graft recipients with stable
graft function (Stable Function group) (P=0.662, one-way ANOVA).
Reverse transcription to cDNA
Prior to reverse transcription of the RNA to cDNA, and irrespective of the amount of RNA
isolated from an individual urine specimen, the RNA isolated from all urine specimens were
adjusted to a concentration of 1μg in 100μl volume. This adjustment of RNA to a consistent
concentration prior to reverse transcription nullifies any differences in urinary sediment size
or RNA yield contributing to differences in mRNA copy number ascertained in the PCR
assays. On the other hand, the type of cells (immune cells vs. renal parenchymal cells), the
activation status of the cells and their state of differentiation could contribute to the
differences in mRNA copy number in the urine of patients with ACR compared to stable
graft function group. Transcripts were then quantified by quantitative RT-PCR assay and
expressed as copies/μg total RNA. Urine samples were considered quality control passed if
in a given sample the 18S rRNA copy number was ≥ 5×107 and TGF-β1 mRNA copy
number was ≥1×102 copies/μg RNA. With these parameters, 3559 (83%) of the 4300 urine
samples were classified as quality control passed.
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Urinary cell mRNA levels diagnostic of ACR
We investigated the hypothesis that urinary cell levels of mRNA are diagnostic of ACR. We
tested this by measuring the 8 pre-specified mRNAs in 43 urine samples matched to 43 ACR
biopsies from 34 patients and comparing the levels to those found in 163 samples matched
to 163 biopsies without rejection (No Rejection Biopsy group, 126 patients) and 1540
samples from the Stable (no Biopsy) group (201 patients with urine specimens). In this
aspect of CTOT-04 study, our objective was to examine whether the urine sample would
serve as a surrogate for the invasive biopsy procedure. Thus, we used matched urine samples
in those who underwent a biopsy. In those who did not undergo a biopsy (Stable [no biopsy]
group), all QC-passed samples were analyzed. In accord with the research hypothesis, 18S-
normalized levels of mRNA for CD3ε, perforin, granzyme B and IP-10 in urinary cells
differed significantly among the ACR, No Rejection Biopsy, and Stable (no biopsy) groups
(P<0.0001 for all 4 mRNAs). Pairwise group comparisons showed that the levels of mRNA
for CD3ε, perforin, granzyme B and IP-10 in the ACR group were higher than the levels in
the No Rejection Biopsy group (P<0.0001 for all 4 mRNAs) and the Stable (no biopsy)
group (P<0.0001 for all 4 mRNAs). The 18s rRNA normalized levels of mRNA for CXCR3
(P=0.06), CD103 (P=0.13) and PI-9 (P=0.38) were not associated with ACR, in contrast to
our single center studies. The reasons may include analysis of levels of mRNA for
association with ACR without 18S rRNA normalization in our earlier single center studies
versus analysis of levels of mRNA for association with ACR after 18S rRNA normalization
in the CTOT-04 study. This is critical as non-normalized urinary cell levels of mRNA for
CD103 (P<0.0001), CXCR3 (P<0.0001) and PI-9 (P=0.002) were all significantly associated
with ACR in the CTOT-04 study in accord with our previous studies.
Development of a model for the diagnosis of ACR
We next developed a prediction model comprised of linear combination of mRNAs to
accurately diagnose ACR. A 3-gene model of 18S-normalized CD3ε mRNA, 18S-
normalized IP-10 mRNA and 18S rRNA (all log10-transformed) emerged as the best-fitting
parsimonious model, yielding a diagnostic signature (−6.1487+0.8534 log10(CD3ε/18S)
+0.6376 log10(IP-10/18S)+1.6464 log10(18S)). This 3-gene signature had an area under the
curve (AUC) of 0.85 (95%CI 0.78 to 0.91, P<0.0001). Our 3-gene formula incorporated
18S-normalized CD3ε mRNA and IP-10 mRNA and 18S rRNA. The rationale for
incorporating both 18S-normalized mRNAs measures and 18S rRNA in the equation were
(i) normalization ensures that the levels of target mRNAs (e.g., IP-10 mRNA) are altered
above and beyond the alteration observed with the reference gene in a given sample; (ii)
normalization is a recommended guideline for reporting PCR assay results [92]; and (iii) the
formula for reporting the levels of mRNA measured using real time PCR assays incorporates
delta CT that is derived by subtracting the CT of reference mRNA from the CT of the target
mRNA [93]. In view of these considerations, we normalized each of the mRNAs measured
using the reference gene, 18S rRNA, and examined for differences in the normalized
measures among the three diagnostic groups: ACR Biopsy group, the No Rejection Biopsy
group and the Stable Function group (Figure 2 and Table S6A in [17]). The absolute
quantification protocol used in our study enabled the discovery that the levels of 18S rRNA,
reported to vary less than most genes recommended as reference genes [94], are also
significantly different between the ACR Biopsy group and the No Rejection Biopsy Group
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or the Stable Function group (Table S6B in [17]). We entered all normalized mRNA
measures and the 18S rRNA in a in a full linear logistic regression model and found that
following backward elimination ACR is best predicted by the parsimonious model of
normalized measures of CD3ε mRNA and IP-10 mRNA and 18S rRNA. In an internal cross
validation using bootstrap resampling, we also found that 18S rRNA enters the model 99%
of the time. We were cognizant that the incorporation of 18S normalized measures and 18S
rRNA in the same equation mostly cancels out normalization of target mRNA with 18S
rRNA. Nevertheless, we retained 18S rRNA in the 3-gene formula since normalized mRNA
measures were used in our comparisons of three diagnostic groups and because a non-
normalized, 2-gene formula of CD3ε mRNA and IP-10 mRNA performed in an identical
fashion to the 3-gene formula containing normalized measures of CD3ε mRNA and IP-10
mRNA and 18S rRNA (AUC 0.8447 vs. 0.8454).
Performance characteristics of the model
Using the cutpoint of −1.213, which maximized Youden’s index, our diagnostic signature
was 79% sensitive and 78% specific to distinguish ACR biopsies from No Rejection
biopsies. Besides the good discrimination, the model was well calibrated as well (Hosmer-
Lemeshow χ2=4.84, p=0.77). The inclusion of granzyme B or perforin did not significantly
improve the diagnostic signature based on IP-10, CD3ε and 18s. This should not detract
from the fact that when considered alone, 18S-normalized levels of granzyme B and perforin
are strongly associated with ACR in CTOT-04. Similarly the AUC for the combination of
18S-normalized mRNAs of perforin, IP-10 and 18S rRNA was 0.84 (95% CI: 0.78 to 0.90;
P<0.0001), only slightly lower than that of our best diagnostic signature, and this
combination discriminated ACR biopsies with a sensitivity of 77% and a specificity of 76%.
This signature correlated very highly (r=0.93) with our 3-gene diagnostic signature.
Validation of the model
We used bootstrap validation to internally validate our model. In an initial set of 500
bootstrap samples, 18S-normalized CD3ε, 18S-normalized IP-10 and 18S remained in the
final backwards elimination models more often than any of the other 6 mRNA measures.
Bootstrap validation of this 3-gene model yielded an optimism-corrected estimate of the
AUC of 0.83, an estimate of the expected value of the AUC in independent samples not used
to derive the diagnostic signature. Thus, the diagnostic model was generalizable and did not
show overfitting.
Urinary Cell 3-Gene Signature Predicts Future Development of ACR
The CTOT-04 study was also designed to determine whether mRNA profiles of sequential
urine specimens obtained at clinically stable time points predict (anticipate) the development
of AR. This analysis showed that the 3-gene signature predicted the future development of
AR as well. Figure 3 shows the average within-person trajectories of the diagnostic
signature, looking backwards from the time of biopsy (time=0), for the ACR biopsy group
and the No Rejection Biopsy group. The trajectories between the two groups were
statistically significant (P<0.0001). In the group of patients in whom the biopsy findings
showed no rejection, the score of the diagnostic signature remained relatively flat and well
below the diagnostic threshold prior to the biopsy. It did not increase at the time of biopsy or
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at anytime during the 270 days preceding the biopsy. However in the group of patients in
whom the first biopsy specimen showed ACR, the score of the diagnostic signature started
to increase around 130 days prior to the biopsy with further marked increase during the 20-
day period prior to the biopsy diagnosis of ACR.
Additional Attributes of the Urinary Cell 3-Gene signature
The 3-gene diagnostic signature was specific for ACR. The signature had an AUC of 0.78
(95%CI: 0.68 to 0.89, P<0.0001) to distinguish the 43 biopsy confirmed ACR from the 31
biopsy confirmed other rejections (Borderline changes, antibody mediated rejection [AMR]
or CAN). We next examined whether the 3-gene signature functions as a response-predictive
biomarker. Among 43 ACR biopsies with paired urine samples, 32 had quality control-
passed urine samples collect at 14±7 days after the incident ACR biopsy. A comparison of
the diagnostic signature values showed a significant decrease from −0.37 at the time of ACR
biopsy to −0.86 at 14±7 days post-biopsy (P=0.05). We further compared the decrease in the
value for the diagnostic signature according to whether the patient was a “responder”,
defined as the follow-up estimated glomerular filtration rate (eGFR) being no higher than it
was at the time of the ACR biopsy or a non-responder to the initial anti-rejection therapy.
eGFR data were available at the time of biopsy and at the follow-up time for 25 of the 32
samples and among these 25, 21 were responders and the remaining 4 were non-responders
based on the above criterion. In the 21 responders, the value for the diagnostic signature
decreased significantly from the baseline value of −0.43 to −1.08 at 14±7 days post biopsy
(P=0.05); in the small number of non-responders, the decrease in the value from +0.12 to
−0.80 was even greater than in the responders (0.92 vs. 0.65), but was not statistically
significant (P=0.20). Of note, the non-responders had higher levels of the diagnostic
signature at the time of biopsy and two weeks later, and among the 21 responders, 7 did not
show a decrease in the value of the diagnostic signature.
The 3-gene signature was diagnostic in patients who underwent for-cause biopsies as well as
in those who underwent surveillance biopsies and was similarly diagnostic across
transplantation sites. The score of the diagnostic signature was not associated with the Banff
grade for ACR. The urine samples from patients who received induction therapy with
interleukin-2 receptor antibodies, as compared with those from patients who received T-
cell–depleting antibodies, had a higher diagnostic score (P<0.001) especially during the first
month after transplantation, but the signature was diagnostic of ACR with either type of
induction therapy. The diagnostic signature was not associated with urinary tract infection,
blood infection or CMV infection (all P>0.05) but was associated with BK virus infection (P
= 0.03). The mean diagnostic score at 4 to 6 months was associated with a decline of 30% or
more in renal allograft function from 6 to 12 months (odds ratio, 2.66; 95% CI, 1.45 to 4.87;
P = 0.002).
Urinary Cell mRNA Profiles Predictive of Chronic Rejection/IF/TA
We have developed a molecular signature based on urinary cell mRNA profile for the
noninvasive diagnosis of kidney allograft fibrosis (IF/TA) [95]. We collected 114 urine
samples at the time of an allograft biopsy from 114 kidney allograft recipients; 48 biopsies
from 48 patients were classified as IF/TA, and 66 biopsies from 66 patients were classified
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as normal biopsies. The biopsies classified as IF/TA were clinically indicated biopsies and
the normal biopsies were surveillance biopsies. We specifically chose a pristine control
group–urine samples from patients with normal biopsy findings in their surveillance
biopsies, as the use biopsies with AR, calcineurin toxicity, or BK virus nephropathy as
controls, may have compromised the development of a robust biomarker that distinguishes
biopsy specimens with IF/TA from biopsy specimens without IF/TA as each of these
conditions may be associated with some degree of fibrosis.
The biopsy-matched urine samples were centrifuged and RNA was extracted from the urine
cell pellet and reverse-transcribed to cDNA. We designed oligonucleotide primers and
fluorogenic probes for the measurement, by preamplification enhanced RT-PCR assay, of
absolute levels of 22 mRNAs of genes associated with fibrosis and the endogenous control
18S rRNA. Our urinary cell mRNA panel was designed with due consideration that multiple
cell types and an inflammatory milieu contribute to the development of fibrosis and that
fibrosis is characterized by the accumulation of extracellular matrix proteins. Our study
cohort was portioned in to a discovery cohort and a validation cohort and statistical analysis,
in addition to protecting against type I error, involved the use of LOESS (locally weighted
scatterplot smoothing) methods to elucidate the potentially non-linear relationship between
two variables since it has the advantage of fitting segments of data without pre-specifying a
specific, usually linear, global function.
Levels of 12 of the 22 mRNAs (vimentin, HGF, α-SMA, fibronectin 1, perforin, PAI1,
TGF-β1, TIMP1, granzyme B, FSP1, CD103, and collagen 1A1) were significantly
associated (P<0.05) with the diagnosis of IF/TA. Of the individual mRNAs, vimentin and
HGF had the highest AUCs and a multigene prediction model of IF/TA was developed
around vimentin because of vimentin’s potential to contribute to the pathogenesis of fibrosis.
Interestingly, after controlling for vimentin mRNA level and the quadratic relationship of
18S rRNA level, we found that none of the previously significant predictors but two of the
previously non-significant predictors, mRNA for tubular transporter NKCC2 and tubular
epithelial cell adhesion molecule E-cadherin, became statistically significant. The composite
score based on the 4-gene signature of vimentin, NKCC2, E-cadherin and 18S rRNA was
highly associated with the diagnosis of IF/TA. The AUC for 4-gene signature was 0.95
(95%CI: 0.90 to 0.99, P<0.0001) and with the use of the optimal cutpoint of 4.5, the
composite score predicted IF/TA with a sensitivity of 93.8% (95%CI: 85.4 to 99.9%) and a
specificity of 84.1% (95%CI: 73.3 to 94.9%).
We then validated the final diagnostic equation predicting IF/TA in an independent
validation set of 38 kidney graft recipients, 16 with biopsy-proven IF/TA and 22 with
normal allograft biopsy results. This 4-gene signature was accurately diagnostic of IF/TA;
the AUC for the diagnosis of fibrosis in the independent validation set was 0.89 (95%CI:
0.78 to 0.99, P<0.0001). At the composite score cutpoint of 4.5, derived in the discovery set,
IF/TA was diagnosed in the validation set with a sensitivity of 87.5% (95%CI: 71.3 to
99.9%) and a specificity of 77.3% (95%CI: 59.8 to 94.8%). We examined the fit of the
prediction model by dividing the discovery and validation sets into sextile of the composite
score. Based on the Hosmer-Lemeshow test, the fit between the observed and the predicted
number of subjects with IF/TA in each of the sextile was excellent (P=0.69) in the discovery
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set. For the validation set, the P-value was 0.04, suggesting a good fit, given that this set was
not involved in the estimation of the model (Figure 4).
Concluding Remarks
Our urinary cell mRNA profiling studies have shown considerable robustness in diagnosing
AR and IF/TA in the kidney allograft and has the potential to provide mechanistic insights
regarding allograft rejection and IF/TA (Figure 5) [69]. It is noteworthy that the multi-center
CTOT-04 trial has not only validated the accuracy of urinary cell mRNA profiling for the
detection of ACR in single center studies but also the utility of urinary cell mRNA profiles
for the prediction of future occurrence of an ACR. It is also noteworthy that the
reproducibility of the urinary cell mRNA protocols across laboratories has been examined
and the overall, gene expression measurements had a correlation greater than 0.938 for the
samples in this independent study [96].
Several challenges remain regarding urinary cell mRNA profiling; can it replace the use of
renal biopsy in many instances where a for-cause biopsy or a surveillance biopsy is currently
performed; can we utilize a standardized urinary gene mRNA profiling protocol as a
monitoring tool to prevent the development of overt AR; can we develop a urinary mRNA
gene signature that will predict the response to anti-rejection treatment? Should in-vivo
immune status of the kidney allograft be reflected accurately by urinary cell mRNA profiles,
transition from the current “one-size fits all” immunosuppressive regimen to a personalized
immunosuppressive regimen could be realized [97]. Recent technical advances such as
massively parallel sequencing should help identify additional candidate biomarkers
informative of diagnosis and prognosis of allograft status and inform gene expression
studies performed in our laboratory and elsewhere.
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Figure 1. A TGF-beta1- centric hypothesis for chronic rejection/chronic allograft nephropathy/
chronic allograft damage
In this formulation, both immune and nonimmune factors are responsible for the allograft
damage and the attendant repair, and the relative contributions of immune and nonimmune
forces vary based on genetic determinants and clinical interventions. In this TGF-β-centric
hypothesis, intrarenal over-expression of TGF-β represents a critical and self-perpetuating
pathogenetic event for the progressive damage to the kidney allograft and attendant decline
in graft function. A therapeutic implication of this conceptualization is that TGF-beta1
blockade may be of benefit in minimizing kidney allograft damage. However, TGF-beta1 is
also a potent immunosuppressant and likely contributes to allograft graft protection and/or
tolerance and TGF-beta blockade could lead to allograft rejection. Selective blockade (i.e.,
blocking the fibrogenic arm but not the immunoregulatory arm) is desirable but remains an
unmet challenge.
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Figure 2. Conceptualization of the kidney allograft as an in-vivo flow cytometer
Interstitial inflammation and tubilitis are the histological hallmarks of acute cellular
rejection in the kidney allograft (left panel). Since acute cellular rejection involves the exit
of T-lymphocytes from the intravascular space and gain of entry into the tubular space, the
kidney allograft could be considered to function as an in-vivo flow cytometer (middle panel)
facilitating the entry of graft destructive/protective T-lymphocytes, other immune cells and
graft parenchymal cells into the urinary space and become available for gene expression
profiling.
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Figure 3. Noninvasive Diagnosis of Acute Cellular Rejection: Retrospective Trajectory of Three-
Gene Diagnostic Signature as a Function of Time Prior to Biopsy Diagnosis of Acute Cellular
Rejection
The LOESS-smoothed average within-person retrospective trajectory of the diagnostic
signature (i.e., the trajectory as a function of the time before biopsy) in urine samples
obtained at or before biopsy that passed quality control are shown for the group of 38 kidney
graft recipients with first biopsy specimens showing acute cellular rejection (201 urine
samples) (Panel A) and the group of 113 patients with specimens showing no rejection (833
urine samples) (Panel B). The diagnostic signature remained relatively flat and well below
the 1.213 threshold that was diagnostic of acute cellular rejection during the 270 days before
biopsy in the group of patients with biopsy findings showing no rejection (Panel C). There
was a significant difference in the trajectories between the acute cellular rejection group and
no rejection biopsy group, with a marked increase in the diagnostic signature during the 20-
day period before the first specimen showing acute cellular rejection (P<0.001) (Panel D).
The y-axis values are diagnostic-signature scores without intrinsic units of measurement and
they were calculated from the logistic-regression equation (6.1487 +0.8534 log10[CD3ε/
18S] + 0.6376 log10[IP-10/18S] + 1.6464 log10[18S]). Absolute levels of CD3ε mRNA,
IP-10 mRNA, and 18S rRNA in the cells from each urine sample were measured by
polymerase-chain-reaction assay, with the units of measurement being copies per microgram
of total RNA for each mRNA measure and copies (×10−6) per microgram of total RNA for
18S rRNA. The mRNA copy numbers were 18S-normalized by dividing the mRNA copy
number by the 18S rRNA copy number in the same sample, and the ratio was log10-
transformed. In all panels the colored bands represent the 95% confidence interval for the
LOESS-smoothed average.
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Figure 4. Noninvasive Diagnosis of IF/TA in the Kidney Allograft: Discovery and Validation of
Urinary Cell Four-Gene Composite Score
To predict IF/TA in the Discovery set, we calculated a composite score based on a logistic
model, from levels of vimentin mRNA, NKCC2 mRNA and E cadherin mRNA and the 18S
rRNA (4-gene signature) in urine samples obtained from the 32 kidney graft recipients with
biopsy-confirmed IF/TA and 44 subjects with stable graft function and with normal allograft
biopsy results. The composite score of the 4-gene signature predicted IF/TA with high
accuracy. Panel A shows the predicted probability of IF/TA (Y-axis) as a logistic function of
the composite score of the 4-gene signature (X-axis). The blue band represents the 95%
confidence interval of the composite score. Panel B shows the receiver-operating-
characteristic curve for the diagnosis of IF/TA using the composite score. The diagnostic
model had an area under the curve of 0.95 (95%CI: 0.90 to 0.99, P<0.0001). At a cutpoint or
4.5, IF/TA was diagnosed with a specificity of 84.1% (95%CI: 73.3 to 94.9%) and a
sensitivity of 93.8% (95%CI: 85.4 to 99.9%) in the discovery set. We used the final
prediction equation derived from the discovery set to calculate the predicted probability of
IF/TA in the validation set of 38 kidney transplant recipients; 16 with biopsy-confirmed
IF/TA and 22 with stable graft function and normal allograft biopsy results. Panel C shows
the receiver-operating characteristic curve of the composite score (derived from the equation
used in the discovery set) applied to the validation set for the diagnosis of IF/TA. The area
under the curve for the diagnosis of IF/TA in the validation set was 0.89 (95%CI: 0.78 to
0.99, P<0.0001). At the original composite score cutpoint of 4.5 derived from the discovery
set, IF/TA was diagnosed in the validation set with a specificity of 77.3% (95%CI: 59.8 to
94.8%) and a sensitivity of 87.5% (95%CI: 71.3 to 99.9%). Panel D shows the predicted and
observed number of kidney graft recipients with IF/TA for each sextile of the composite
score within the discovery and validation sets. Based on the Hosmer-Lemeshow test, the fit
between the observed and the predicted number of subjects with IF/TA in each of the
sextiles was excellent (P=0.69) in the discovery set (left half of Fig. 4D). For the validation
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set (right half of Fig. 4D), the P value was 0.04, suggesting a good fit, given that this set was
not involved in the estimation of the model.
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Figure 5. Key Molecular Events During Acute Cellular Rejection of the Kidney Allograft
The immune repertory contributing to acute cellular rejection involves multiple cell types,
cytokines and chemokines and their ligands. T-lymphocytes are the principal effector cells
and dendritic cells are the primary antigen presenting cells. In this minimalist model, the
chemokine IP-10 and its receptor CXCR3, expressed on T-lymphocytes, facilitate the
trafficking of alloreactive T-lymphocytes in to the kidney graft. Intraepithelial homing of the
T-lymphocytes is then effected by the physical interaction between CD103 expressed on the
T-lymphocytes and E-cadherin displayed on the kidney tubular epithelial cells. The
activated/alloreactive T-lymphocytes then employ perforin and granzyme to mediate
parenchymal cell damage, which is antagonized in part by the endogenous antagonist
proteinase inhibitor-9 (PI-9). Counter-regulatory forces are exerted by FoxP3 expressing
regulatory T-lymphocytes (Tregs) and help dampen the anti-allograft response and the
ultimate outcome of an episode of acute rejection is determined in part by the balance
between the graft destructive cells such as cytotoxic T cells and graft protective Tregs.
Although the cells with different functional attributes are depicted here to have distinct
pedigrees, transition from one functional type to another (plasticity) is feasible based on the
cells versatility and environmental cues. In this T-lymphocyte -centric formulation
deterministic of allograft destiny, the antigen-experienced T-lymphocytes provide help to B-
lymphocytes and facilitate antibody-mediated rejection. Acute rejection is a precursor of
chronic rejection manifested histologically by interstitial fibrosis/tubular atrophy (IF/TA).
Acute rejection-associated tissue injury, de-differentiation and repair (epithelial/endothelial-
mesenchymal transition) contribute to the pathogenesis of IF/TA and progressive loss of
allograft function. The levels of mRNA encoding vimentin, αSMA, E-cadherin and NKCC2
in urinary cells reflect the cellular events associated with IF/TA quantitatively. The mRNAs,
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colored red in the schematic illustration, have all been detected and quantified using urinary
cell mRNA profiling and found to be associated with human kidney allograft status.
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